No Evidence of Increased Degenerative Disc Disease Risk from Testosterone in Trans Men
Based on current clinical guidelines and available research, there is no established link between intramuscular testosterone therapy in transgender males and increased risk of degenerative disc disease. The major clinical practice guidelines for transgender hormone therapy do not identify degenerative disc disease as a recognized adverse effect of testosterone treatment 1, 2.
What the Guidelines Actually Monitor
The Endocrine Society and recent comprehensive reviews identify the following as documented risks requiring monitoring in trans men on testosterone 1, 2:
- Cardiovascular factors: Blood pressure, lipid profiles (increased triglycerides, decreased HDL)
- Hematologic effects: Erythrocytosis/polycythemia (elevated hematocrit and hemoglobin)
- Metabolic changes: Weight gain, insulin resistance markers
- Bone health: Risk related to inadequate testosterone dosing or hypogonadism, not excess
- Hepatic function: Liver enzyme monitoring
Notably absent from any guideline is degenerative disc disease surveillance or warnings.
Emerging Research Suggests Potential Protective Effects
Interestingly, the limited available research on testosterone and intervertebral disc biology suggests the opposite of harm:
Testosterone may enhance disc matrix synthesis: A 2014 study demonstrated that physiological testosterone concentrations improved chondrogenic extracellular matrix production specifically in male nucleus pulposus cells, increasing collagen type II and aggrecan expression 3
Anti-inflammatory properties: Recent 2026 research showed that testosterone (as dihydrotestosterone) attenuated pro-inflammatory gene expression in both nucleus pulposus and annulus fibrosus cells, potentially protecting against inflammatory disc degeneration 4
Estrogen deficiency is the concern: A 2023 narrative review identified that estrogen-deficient states (not testosterone excess) negatively impact disc function and structural integrity 5
Clinical Implications
You can reassure transgender male patients that testosterone therapy does not carry a known risk for degenerative disc disease. The standard monitoring protocol should focus on the well-established risks 1, 2:
- Complete blood count every 3 months in the first year, then 1-2 times yearly (watching for erythrocytosis)
- Lipid panel and blood pressure monitoring
- Liver function tests
- Bone density assessment only if risk factors present or inadequate hormone dosing
Important Caveat
The cardiovascular mortality data in trans men remains limited with low to very low certainty of evidence for long-term outcomes 6. However, this relates to cardiovascular events, not musculoskeletal or spinal pathology. The absence of any mention of degenerative disc disease in systematic reviews of testosterone adverse effects is telling—if this were a clinically significant problem, it would have emerged in the literature by now.
The theoretical concern about testosterone and disc degeneration lacks both clinical and biological support. If anything, the mechanistic data suggests testosterone may support disc health through enhanced matrix production and anti-inflammatory effects in male disc cells.